Publication
CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.
Zhaoyuan Zhang, Jiaqi Fu, Xuemin Li, Yi Yang, Zehan Li, Yalu Wu, Zhongqian Yin, Junfeng Yu, Hao Zheng, Guangtao Xiang
Biochemical and biophysical research communicationsSep 18, 2026PMID 42772182doi:10.1016/j.bbrc.2026.154610 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Claudin 18 isoform 2 (CLDN18.2) is a therapeutic target in solid tumors, but its contribution to chemotherapy response remains unclear. We examined whether CLDN18.2 targeting increases drug sensitivity and whether this is accompanied by changes in solute carrier family 7 member 11 (SLC7A11)…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.